Shares of Scancell Holdings Plc (LON: SCLP) today surged 24.7% after the company agreed to partner with Cobra Biologics to manufacture plasmid DNA required for use in its COVIDITY Phase 1 clinical trial for its COVID-19 vaccine in 2021.
Innovate UK is funding the project via a grant award to the consortium of Scancell, the University of Nottingham, and Trent University.
Today’s deal covers the good manufacturing practice (GMP) production of plasmid DNA needed to generate the inoculation against SARS-CoV-2.
Interested in investing after today’s move?
XTB gives investors access to thousands of UK and international stocks,
including fractional shares from just £1.
Explore stocks with XTB →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to invest in the stocks making the news?
Go from following the market to investing in it, with access to thousands
of stocks across major UK and international markets.
See available stocks →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Own the stocks you’re reading about
Invest in real shares across the UK, US and other major global markets
through XTB, all from one investment account.
Explore XTB shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
You don’t need to buy a whole share
Fractional shares let you invest from just £1, giving you more control
over how much you put into individual companies.
Explore fractional shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to see how XTB works first?
Explore the platform with an XTB demo account before deciding whether
you want to invest with real money.
Try the XTB demo →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
GMP production is a major breakthrough given that it makes it possible to manufacture vaccines at scale and to therapeutic-grade standards.
The second-generation COVID-19 vaccine is scheduled to start Phase 1 clinical trials in 2021.
“Our collaboration with Cobra is critical to us moving forward with our novel SARS-CoV-2 vaccine into the planned phase I clinical trial, COVIDITY,” said chief executive, Dr Cliff Holloway.
Adding:
“Cobra has the expertise needed to produce clinical-grade plasmid at scale and we look forward to working with them to advance our vaccine and demonstrate its potential effectiveness and protection against COVID-19.”
Scancell Holdings share price
Scancell shares today surged 24.7% to trade at 20.90p having ended Thursday’s session trading at 16.75p.
People who read this also read:
